Lightstone E - Search Results

Year	Number of Results
1988	1
1989	1
1990	2
1991	4
1992	1
1993	1
1997	1
2022	2
2023	2
2025	0

1

Valuing Health Gain from Composite Response Endpoints for Multisystem Diseases.

Gavan SP, Bruce IN, Payne K; MASTERPLANS Consortium. Gavan SP, et al. Value Health. 2023 Jan;26(1):115-122. doi: 10.1016/j.jval.2022.07.001. Epub 2022 Aug 23. Value Health. 2023. PMID: 36008224 Free article.

2

Hospital restructuring initiatives in Canada.

Shamian J, Lightstone EY. Shamian J, et al. Among authors: lightstone ey. Med Care. 1997 Oct;35(10 Suppl):OS62-9. doi: 10.1097/00005650-199710001-00008. Med Care. 1997. PMID: 9339777

3

Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial.

McDonald S, Yiu S, Su L, Gordon C, Truman M, Lisk L, Solomons N, Bruce IN; MASTERPLANS Consortium. McDonald S, et al. Lupus Sci Med. 2022 May;9(1):e000584. doi: 10.1136/lupus-2021-000584. Lupus Sci Med. 2022. PMID: 35640982 Free PMC article. Clinical Trial.

4

Deconvolution of whole blood transcriptomics identifies changes in immune cell composition in patients with systemic lupus erythematosus (SLE) treated with mycophenolate mofetil.

Akthar M, Nair N, Carter LM, Vital EM, Sutton E, McHugh N; British Isles Lupus Assessment Group Biologics Register (BILAG BR) Consortium; MASTERPLANS Consortium; Bruce IN, Reynolds JA. Akthar M, et al. Arthritis Res Ther. 2023 Jun 30;25(1):111. doi: 10.1186/s13075-023-03089-5. Arthritis Res Ther. 2023. PMID: 37391799 Free PMC article.

5

Hyper-reactivity of mouse CD45RA- T cells.

Lightstone E, Marvel J, Mitchison A. Lightstone E, et al. Eur J Immunol. 1993 Sep;23(9):2383-6. doi: 10.1002/eji.1830230952. Eur J Immunol. 1993. PMID: 8370417

6

Antigen presentation by dendritic cells provides optimal stimulation for the production of interleukin (IL) 2, IL 4 and interferon-gamma by allogeneic T cells.

Ellis J, Chain BM, Davies DH, Ibrahim MA, Katz DR, Kaye PM, Lightstone E. Ellis J, et al. Among authors: lightstone e. Eur J Immunol. 1991 Nov;21(11):2803-9. doi: 10.1002/eji.1830211123. Eur J Immunol. 1991. PMID: 1834471

7

CD45RA is detected in all thymocyte subsets defined by CD4 and CD8 by using three-colour flow cytometry.

Lightstone EB, Marvel J. Lightstone EB, et al. Immunology. 1990 Dec;71(4):467-72. Immunology. 1990. PMID: 2279733 Free PMC article.

8

The CD45RA molecule is expressed in naive murine CTL precursors but absent in memory and effector CTL.

Marvel J, Lightstone E, Samberg NL, Ettinghausen D, Stauss HJ. Marvel J, et al. Among authors: lightstone e. Int Immunol. 1991 Jan;3(1):21-8. doi: 10.1093/intimm/3.1.21. Int Immunol. 1991. PMID: 1828693

9

Anti-CD45RA antibodies increase the proliferation of mouse T cells to phytohemagglutinin through the interleukin 2/interleukin 2 receptor pathway.

Marvel J, Poirier G, Lightstone E. Marvel J, et al. Among authors: lightstone e. Eur J Immunol. 1989 Nov;19(11):2005-10. doi: 10.1002/eji.1830191106. Eur J Immunol. 1989. PMID: 2532137

10

In the mouse the maturation stage of the peripheral CD4+ CD45RA+ subset is different from that of the CD8+ CD45RA+ subset.

Lightstone EB, Wyllie D, Marvel J. Lightstone EB, et al. Eur J Immunol. 1991 Sep;21(9):2161-5. doi: 10.1002/eji.1830210926. Eur J Immunol. 1991. PMID: 1679713

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

14 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Results by year